Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-28 @ 12:05 AM
Study NCT ID:
NCT04455594
Status:
UNKNOWN
Last Update Posted:
2020-07-02
First Post:
2020-06-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-10
Completion Date Type:
ESTIMATED
First Submit Date:
2020-06-19
First Submit QC Date:
None
Study First Post Date:
2020-07-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-06-30
Last Update Post Date:
2020-07-02
Last Update Post Date Type:
ACTUAL